Development of CAR T Cells Designed to Improve Antitumor Efficacy and Safety

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2017 Mar 27

PMID 28342824

Citations 50

Authors

Janneke E Jaspers

Renier J Brentjens

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown promising efficacy against hematologic malignancies. Antitumor activity of CAR T cells, however, needs to be improved to increase therapeutic efficacy in both hematologic and solid cancers. Limitations to overcome are 'on-target, off-tumor' toxicity, antigen escape, short CAR T cell persistence, little expansion, trafficking to the tumor and inhibition of T cell activity by an inhibitory tumor microenvironment. Here we will discuss how optimizing the design of CAR T cells through genetic engineering addresses these limitations and improves the antitumor efficacy of CAR T cell therapy in pre-clinical models.

Citing Articles

Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy.

Gergely B, Vereb M, Rebenku I, Vereb G, Szoor A Cancers (Basel). 2025; 17(5).

PMID: 40075578 PMC: 11898473. DOI: 10.3390/cancers17050731.

[Advances in Research on Cell Metabolic Interactions in the Tumor Microenvironment].

Wu P, Yang Z, Li Q, Wang D Sichuan Da Xue Xue Bao Yi Xue Ban. 2024; 55(2):482-489.

PMID: 38645846 PMC: 11026886. DOI: 10.12182/20240360606.

Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.

Kashyap D, Salman H Int J Mol Sci. 2024; 25(7).

PMID: 38612592 PMC: 11011362. DOI: 10.3390/ijms25073780.

Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.

Wang Y, Li Y Curr Pharm Biotechnol. 2024; 25(15):2001-2011.

PMID: 38310449 DOI: 10.2174/0113892010265228231116073012.

Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.

Haines N, Fowler M, Zeh B, Kriete C, Bai Q, Wakefield M Med Oncol. 2024; 41(3):67.

PMID: 38286890 DOI: 10.1007/s12032-023-02281-6.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

von Kempis J, Schwarz H, Lotz M . Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin. Osteoarthritis Cartilage. 1998; 5(6):394-406. DOI: 10.1016/s1063-4584(97)80044-1. View

Morsut L, Roybal K, Xiong X, Gordley R, Coyle S, Thomson M . Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016; 164(4):780-91. PMC: 4752866. DOI: 10.1016/j.cell.2016.01.012. View

Koneru M, OCearbhaill R, Pendharkar S, Spriggs D, Brentjens R . A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015; 13:102. PMC: 4438636. DOI: 10.1186/s12967-015-0460-x. View

Koneru M, Purdon T, Spriggs D, Koneru S, Brentjens R . IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors . Oncoimmunology. 2015; 4(3):e994446. PMC: 4404840. DOI: 10.4161/2162402X.2014.994446. View

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

Lanitis E, Poussin M, Klattenhoff A, Song D, Sandaltzopoulos R, June C . Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2014; 1(1):43-53. PMC: 3881605. DOI: 10.1158/2326-6066.CIR-13-0008. View

Turtle C, Hanafi L, Berger C, Hudecek M, Pender B, Robinson E . Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016; 8(355):355ra116. PMC: 5045301. DOI: 10.1126/scitranslmed.aaf8621. View

10.

Schwarz H, Tuckwell J, Lotz M . A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene. 1993; 134(2):295-8. DOI: 10.1016/0378-1119(93)90110-o. View

11.

Pegram H, Lee J, Hayman E, Imperato G, Tedder T, Sadelain M . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-41. PMC: 3359735. DOI: 10.1182/blood-2011-12-400044. View

12.

Zhang L, Kerkar S, Yu Z, Zheng Z, Yang S, Restifo N . Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011; 19(4):751-9. PMC: 3070103. DOI: 10.1038/mt.2010.313. View

13.

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24(6):1160-70. PMC: 2888148. DOI: 10.1038/leu.2010.75. View

14.

Leonard J, Sherman M, Fisher G, Buchanan L, Larsen G, Atkins M . Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90(7):2541-8. View

15.

Minagawa K, Jamil M, Al-Obaidi M, Pereboeva L, Salzman D, Erba H . In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One. 2016; 11(12):e0166891. PMC: 5132227. DOI: 10.1371/journal.pone.0166891. View

16.

Srivastava S, Koch M, Pepper M, Campbell D . Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med. 2014; 211(5):961-74. PMC: 4010906. DOI: 10.1084/jem.20131556. View

17.

Quintarelli C, Vera J, Savoldo B, Giordano Attianese G, Pule M, Foster A . Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007; 110(8):2793-802. PMC: 2018664. DOI: 10.1182/blood-2007-02-072843. View

18.

Ren J, Liu X, Fang C, Jiang S, June C, Zhao Y . Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2016; 23(9):2255-2266. PMC: 5413401. DOI: 10.1158/1078-0432.CCR-16-1300. View

19.

Cella M, Scheidegger D, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996; 184(2):747-52. PMC: 2192696. DOI: 10.1084/jem.184.2.747. View

20.

Kerkar S, Leonardi A, van Panhuys N, Zhang L, Yu Z, Crompton J . Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther. 2013; 21(7):1369-77. PMC: 3702103. DOI: 10.1038/mt.2013.58. View